Yun Luan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yun Luan has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Chao Sun
Institute of Medical Science, Central Research Laboratory, the Second Hospital of Shandong University, 250033, China
11 shared publicationsJue Wang
Institute of Medical Sciences, The Second Hospital of Shandong University, No. 247, Beiyuan Dajie, Jinan, 250000, PR China
11 shared publicationsQian Xin
Institute of Medical Sciences, The Second Hospital of Shandong University, No. 247, Beiyuan Dajie, Jinan, 250000, PR China
11 shared publicationsWen Jiang
Institute of Medical Sciences, The Second Hospital of Shandong University, Jinan, PR China
8 shared publicationsZhaohua Zhang
Department of Pediatrics, the Second Hospital, Cheeloo College of Medicine, Shandong University
6 shared publicationsShanshan Zhang
Department of Emergency,The Second Hospital Shandong University
5 shared publications
Latest Publications
- Open Access
- 17 September 2024
- Published by Elsevier in Experimental Cell Research
- Vol. 442 (2) , 114256
MSC-derived exosomes attenuates pulmonary hypertension via inhibiting pulmonary vascular remodeling
- 17 September 2024
- Published by Elsevier in Experimental Cell Research
- Vol. 442 (2) , 114256
Open AccessMSC-derived exosomes attenuates pulmonary hypertension via inhibiting pulmonary vascular remodeling
- Open Access
- 19 March 2024
- Published by Elsevier in Materials Today Bio
- Vol. 26, 101029
Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor
- 19 March 2024
- Published by Elsevier in Materials Today Bio
- Vol. 26, 101029
Open AccessEffective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor
- 2 November 2023
- Published by Elsevier in Chinese Chemical Letters
- Vol. 35 (8)
Inhalation of taraxasterol loaded mixed micelles for the treatment of idiopathic pulmonary fibrosis
- 2 November 2023
- Published by Elsevier in Chinese Chemical Letters
- Vol. 35 (8)
Inhalation of taraxasterol loaded mixed micelles for the treatment of idiopathic pulmonary fibrosis
- Open Access
- 14 January 2023
- Published by Codon Publications in Journal of Kidney Cancer
- Vol. 10 (1) , 1-8
(RETRACTED) Ligustrazine Inhibits the Migration and Invasion of Renal Cell Carcinoma
Ligustrazine is a Chinese herb (Chuanxiong) approved for use as a medical drug in China. Recent evidence suggests that ligustrazine has promising antitumor properties. Our preliminary results showed that ligustrazine could inhibit the growth of human renal cell carcinoma (RCC) cell lines. However, the complicated molecular mechanism has not been fully revealed. Therefore, the purpose of this study to investigate the mechanism of ligustrazine resistance in human RCC cells. Cell proliferation, migration, invasion, and colony-formation ability of RCC cells A498 were detected by MTT assay, clonal formation rates, and transwell chamber assay in vitro. The expression of epithelial–mesenchymal transition (EMT)–related proteins were analyzed using western blot test. The effect of ligustrazine on the growth of A498 cells in nude mice was investigated in vivo. Our results showed that ligustrazine could significantly inhibit the proliferation, migration, and invasion of A498 both in vivo and vitro. Western blot analysis showed that the expressions of EMT-related, N-cadherin, snail, and slug proteins were significantly decreased in A498 in the ligustrazine treatment group. This study indicated that ligustrazine could significantly inhibit the malignant biological behaviors of RCC cell lines, possibly by inhibiting the EMT process.
- 14 January 2023
- Published by Codon Publications in Journal of Kidney Cancer
- Vol. 10 (1) , 1-8
Open Access(RETRACTED) Ligustrazine Inhibits the Migration and Invasion of Renal Cell Carcinoma
Ligustrazine is a Chinese herb (Chuanxiong) approved for use as a medical drug in China. Recent evidence suggests that ligustrazine has promising antitumor properties. Our preliminary results showed that ligustrazine could inhibit the growth of human renal cell carcinoma (RCC) cell lines. However, the complicated molecular mechanism has not been fully revealed. Therefore, the purpose of this study to investigate the mechanism of ligustrazine resistance in human RCC cells. Cell proliferation, migration, invasion, and colony-formation ability of RCC cells A498 were detected by MTT assay, clonal formation rates, and transwell chamber assay in vitro. The expression of epithelial–mesenchymal transition (EMT)–related proteins were analyzed using western blot test. The effect of ligustrazine on the growth of A498 cells in nude mice was investigated in vivo. Our results showed that ligustrazine could significantly inhibit the proliferation, migration, and invasion of A498 both in vivo and vitro. Western blot analysis showed that the expressions of EMT-related, N-cadherin, snail, and slug proteins were significantly decreased in A498 in the ligustrazine treatment group. This study indicated that ligustrazine could significantly inhibit the malignant biological behaviors of RCC cell lines, possibly by inhibiting the EMT process.
- 25 November 2021
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 44 (2) , 175-180
A review of BMP and Wnt signaling pathway in the pathogenesis of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a chronic disease characterized by a progressive elevation in mean pulmonary arterial pressure. This occurs due to abnormal remodeling of small peripheral lung vasculature resulting in progressive occlusion of the artery lumen that eventually causes right heart failure and death. Current therapeutic options for PAH are limited and focused mainly on reversal of pulmonary vasoconstriction and proliferation of vascular cells. Although these treatments can relieve disease symptoms, PAH remains a progressive lethal disease. Bone morphogenetic proteins (BMPs) and their receptors were required for PAH-induced right ventricular hypertrophy. Emerging data suggest that restoration of BMP type II receptor (BMPR2) signaling in PAH is a promising alternative that could prevent and reverse pulmonary vascular remodeling. BMPR2 mutations have been identified in >70% of familial and roughly 15% of sporadic PAH cases. Wingless (Wnt) are a family of secreted glycoproteins with varying expression patterns and a range of functions, Wnt signaling pathway is divided into canonical signaling pathway and non-canonical signaling pathway. A recent study reports that interaction between BMP and Wnt closely associated with lung development, those cascade coordination regulation stem cell fate which determine lung branching morphogenes. The promoting effect of BMPR2 on proliferation, survival, and motility of endothelial cells was through recruiting Wnts signaling pathway, the interaction between BMP and Wnt closely associated with lung development. Therefore, in this review, we outline the latest advances of BMP and Wnt signaling pathway in the pathogenesis of PAH and disease progression.
- 25 November 2021
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 44 (2) , 175-180
A review of BMP and Wnt signaling pathway in the pathogenesis of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a chronic disease characterized by a progressive elevation in mean pulmonary arterial pressure. This occurs due to abnormal remodeling of small peripheral lung vasculature resulting in progressive occlusion of the artery lumen that eventually causes right heart failure and death. Current therapeutic options for PAH are limited and focused mainly on reversal of pulmonary vasoconstriction and proliferation of vascular cells. Although these treatments can relieve disease symptoms, PAH remains a progressive lethal disease. Bone morphogenetic proteins (BMPs) and their receptors were required for PAH-induced right ventricular hypertrophy. Emerging data suggest that restoration of BMP type II receptor (BMPR2) signaling in PAH is a promising alternative that could prevent and reverse pulmonary vascular remodeling. BMPR2 mutations have been identified in >70% of familial and roughly 15% of sporadic PAH cases. Wingless (Wnt) are a family of secreted glycoproteins with varying expression patterns and a range of functions, Wnt signaling pathway is divided into canonical signaling pathway and non-canonical signaling pathway. A recent study reports that interaction between BMP and Wnt closely associated with lung development, those cascade coordination regulation stem cell fate which determine lung branching morphogenes. The promoting effect of BMPR2 on proliferation, survival, and motility of endothelial cells was through recruiting Wnts signaling pathway, the interaction between BMP and Wnt closely associated with lung development. Therefore, in this review, we outline the latest advances of BMP and Wnt signaling pathway in the pathogenesis of PAH and disease progression.
- 2 September 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (12) , 1654-1662
Mesenchymal Stromal Cell-derived Exosomes Attenuate Experimental Pulmonary Arterial Hypertension
Background: Pulmonary arterial hypertension (PH) is a chronic disease that ultimately progresses to right ventricular failure and death, until now there is still lack of effective treatment applied. The purpose of the present study was to observe the protective effect of mesenchymal stromal cell derived exosomes (MSC-EXO) against experimental pulmonary arterial hypertension (PH) and right ventricular failure. Methods: All the experimental rats received an intraperitoneal injection of 50 mg/kg monocrotaline to induce PH model. Three weeks after the model was successfully established, the cell Culture Media (CM) or MSC-EXO derived from human umbilical cord was administered daily via the tail vein. All animals were randomly divided into 4 groups: Control (saline-treated), MCT-PH, MCT-CM and MCT-EXO groups. Post-operation, hemodynamic data and index of right ventricular hypertrophy (RVHI) were recorded to evaluate the inhibition of MSC-EXO on MCT-induced PH. Histology, immunohistochemistry and western blot were used to analyze the effect of MSC-EXO against vascular remodeling and further reveal the mechanism. Results: In the present study, our results showed that MSC-EXO administration could significantly reduce the right ventricular systolic pressure (RVSP) and RVHI, suppress the pulmonary vascular remodeling and the endothelialmesenchymal transition (EndMT) process. Conclusion: Our results provided the firm information for a new method in treatment of PH, the mechanism may be may be related with the inhibition of vascular remodeling and EndMT.
- 2 September 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (12) , 1654-1662
Mesenchymal Stromal Cell-derived Exosomes Attenuate Experimental Pulmonary Arterial Hypertension
Background: Pulmonary arterial hypertension (PH) is a chronic disease that ultimately progresses to right ventricular failure and death, until now there is still lack of effective treatment applied. The purpose of the present study was to observe the protective effect of mesenchymal stromal cell derived exosomes (MSC-EXO) against experimental pulmonary arterial hypertension (PH) and right ventricular failure. Methods: All the experimental rats received an intraperitoneal injection of 50 mg/kg monocrotaline to induce PH model. Three weeks after the model was successfully established, the cell Culture Media (CM) or MSC-EXO derived from human umbilical cord was administered daily via the tail vein. All animals were randomly divided into 4 groups: Control (saline-treated), MCT-PH, MCT-CM and MCT-EXO groups. Post-operation, hemodynamic data and index of right ventricular hypertrophy (RVHI) were recorded to evaluate the inhibition of MSC-EXO on MCT-induced PH. Histology, immunohistochemistry and western blot were used to analyze the effect of MSC-EXO against vascular remodeling and further reveal the mechanism. Results: In the present study, our results showed that MSC-EXO administration could significantly reduce the right ventricular systolic pressure (RVSP) and RVHI, suppress the pulmonary vascular remodeling and the endothelialmesenchymal transition (EndMT) process. Conclusion: Our results provided the firm information for a new method in treatment of PH, the mechanism may be may be related with the inhibition of vascular remodeling and EndMT.
- Open Access
- 5 May 2021
- Published by Springer Nature in Research Square
The Protective of hUC- MSCs Derived Exosomes on Pulmonary Vascular Remodeling in Experimental Pulmonary Hypertension
Pulmonary hypertension (PH) is a life-threatening disease, so far no effective method for it. Therefore, the main aim of the present study was to investigate the protective effect of exosomes derived from human umbilical cord msenchymal stem cells (hUC-MSCs) on PH vascular remodeling and reveal the underlying mechanism. We established monocrotaline-induced PH (MCT-PH) rats and hypoxia induced pulmonary artery smooth muscle cells (H-PASMC) model in vivo and vitro . Exosomes derived from hUC-MSCs (hUC-MSC-EXO) were administration, respectively. Post-operation, our results showed that hUC-MSC-EXO significantly reduced the right ventricular systolic pressure (RVSP) and the right ventricular hypertrophy index (RVHI), inhibited pulmonary vascular remodeling. Furthermore, the hypoxia-induced PASMC proliferation was obviously inhibited in vitro . More-importantly, the results showed that the protein expression levels of BMPR2, BMP-4 and BMP-9 were significantly increased, but the levels of nuclear factor-κB (NF-κB) p65 and bone morphogenetic protein (BMP) antagonists Gremlin-1 were significantly decreased in hUC-MSC-EXO than that in MCT-PH and hypoxia-induced PASMC groups in vivo and vitro , respectively. Taken together, this present study provided the firm information for the use of this new method in treatment of PH, and the mechanism was associated with regulation of BMP signaling pathway.
- 5 May 2021
- Published by Springer Nature in Research Square
Open AccessThe Protective of hUC- MSCs Derived Exosomes on Pulmonary Vascular Remodeling in Experimental Pulmonary Hypertension
Pulmonary hypertension (PH) is a life-threatening disease, so far no effective method for it. Therefore, the main aim of the present study was to investigate the protective effect of exosomes derived from human umbilical cord msenchymal stem cells (hUC-MSCs) on PH vascular remodeling and reveal the underlying mechanism. We established monocrotaline-induced PH (MCT-PH) rats and hypoxia induced pulmonary artery smooth muscle cells (H-PASMC) model in vivo and vitro . Exosomes derived from hUC-MSCs (hUC-MSC-EXO) were administration, respectively. Post-operation, our results showed that hUC-MSC-EXO significantly reduced the right ventricular systolic pressure (RVSP) and the right ventricular hypertrophy index (RVHI), inhibited pulmonary vascular remodeling. Furthermore, the hypoxia-induced PASMC proliferation was obviously inhibited in vitro . More-importantly, the results showed that the protein expression levels of BMPR2, BMP-4 and BMP-9 were significantly increased, but the levels of nuclear factor-κB (NF-κB) p65 and bone morphogenetic protein (BMP) antagonists Gremlin-1 were significantly decreased in hUC-MSC-EXO than that in MCT-PH and hypoxia-induced PASMC groups in vivo and vitro , respectively. Taken together, this present study provided the firm information for the use of this new method in treatment of PH, and the mechanism was associated with regulation of BMP signaling pathway.
- Open Access
- 9 January 2021
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 9 (1) , e00703
Protective effect of baicalin against pulmonary arterial hypertension vascular remodeling through regulation of TNF‐α signaling pathway
Pulmonary arterial hypertension (PAH) is a progressive cardiovascular disease with high mortality. However, there were no efficient medical drugs for PAH to enormously improve the survival and quality of life measures. The present study aimed to explore the protective effect of baicalin against experimental PAH in vivo and vitro. All the experimental rats received intraperitoneal injection of monocrotaline (MCT) to induce PAH model. Baicalin was given by intragastric administration from 2 days after MCT injection. Forty animals were randomly divided into four groups: Control, MCT, saline‐, and baicalin‐treated groups (n = 10 in each). Post‐operation, hemodynamic data, and index of right ventricular hypertrophy (RVHI) were recorded to evaluate the inhibition of baicalin on MCT‐induced PAH. Furthermore, pulmonary artery smooth muscle cells (PASMCs) model induced by tumor necrosis factor‐α (TNF‐α) was used to observe the inhibition of vascular cells proliferation in vitro. The results demonstrated that baicalin significantly attenuated MCT‐induced right ventricular systolic pressure (RVSP), the index of right ventricular hypertrophy, and vessel wall thickness; inhibit inflammatory and cell proliferation induced by MCT or TNF‐α, respectively. In addition, we found that baicalin might protect against experimental PAH via regulating the TNF‐α/BMPR2 signaling pathway.
- 9 January 2021
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 9 (1) , e00703
Open AccessProtective effect of baicalin against pulmonary arterial hypertension vascular remodeling through regulation of TNF‐α signaling pathway
Pulmonary arterial hypertension (PAH) is a progressive cardiovascular disease with high mortality. However, there were no efficient medical drugs for PAH to enormously improve the survival and quality of life measures. The present study aimed to explore the protective effect of baicalin against experimental PAH in vivo and vitro. All the experimental rats received intraperitoneal injection of monocrotaline (MCT) to induce PAH model. Baicalin was given by intragastric administration from 2 days after MCT injection. Forty animals were randomly divided into four groups: Control, MCT, saline‐, and baicalin‐treated groups (n = 10 in each). Post‐operation, hemodynamic data, and index of right ventricular hypertrophy (RVHI) were recorded to evaluate the inhibition of baicalin on MCT‐induced PAH. Furthermore, pulmonary artery smooth muscle cells (PASMCs) model induced by tumor necrosis factor‐α (TNF‐α) was used to observe the inhibition of vascular cells proliferation in vitro. The results demonstrated that baicalin significantly attenuated MCT‐induced right ventricular systolic pressure (RVSP), the index of right ventricular hypertrophy, and vessel wall thickness; inhibit inflammatory and cell proliferation induced by MCT or TNF‐α, respectively. In addition, we found that baicalin might protect against experimental PAH via regulating the TNF‐α/BMPR2 signaling pathway.
- 28 November 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 21 (13) , 1386-1393
The Protective of Baicalin on Myocardial Ischemia-Reperfusion Injury
Background: The aim of this study was to explore the inhibitory effect of baicalin on myocardial apoptosis induced by Ischemia-Reperfusion (I/R).Methods: Sprague Dawley rats' heart and myocardial cells I/R model were established in vivo and vitro, then 100 mg/kg and 10 μmol/l baicalin were administrated, respectively. The experiment was randomly divided into 4 groups (n=10): Control; I/R; IR+DMEM; and I/R+baicalin groups. Postoperation, the Left Ventricular (LV) End-Diastolic Pressure (LVEDP), the maximum velocity of LV contraction (dP/dtmax) and the maximum velocity of LV diastole (dP/dtmin) were recorded by the transthoracic echocardiography; the myocardial apoptosis percentage was analyzed by Annexin VFITC/ PI and TUNEL staining, and the apoptosis gene and protein were detected by RT-PCR and western blot. Furthermore, the protein expression of the calcium-sensing receptor (CaSR) and ERK1/2 phosphorylation were observed by western blot and Fura-2-acetoxymethyl ester. Moreover, primary rats’ cardiomyocytes were cultured and ERK1/2 specific inhibitor PD98059 was added to the culture medium. The cell survival rate, vitality and apoptosis were detected by MTT, lactate dehydrogenase (LDH) and TUNEL staining assay Kit, respectively.Results: Our present study showed that baicalin significantly improved LV hemodynamic parameters and myocardial apoptosis in myocardial I/R injury rats. Furthermore, we found that baicalin could down-regulate the protein expression of CaSR, but up-regulate the protein expression of ERK1/2. Furthermore, when the cells were pretreated with ERK1/2 inhibitor PD98059, the cells survival rate significantly decreased, but LDH activity and apoptosis significantly increased. The results indicated that the effect of baicalin on myocardial I/R injury could be inhibited by ERK1/2 inhibitor.Conclusion: In conclusion, our data suggests that baicalin attenuates I/R-induced myocardial injury maybe through the suppression of the CaSR/ERK1/2 signaling pathway.
- 28 November 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 21 (13) , 1386-1393
The Protective of Baicalin on Myocardial Ischemia-Reperfusion Injury
Background: The aim of this study was to explore the inhibitory effect of baicalin on myocardial apoptosis induced by Ischemia-Reperfusion (I/R).Methods: Sprague Dawley rats' heart and myocardial cells I/R model were established in vivo and vitro, then 100 mg/kg and 10 μmol/l baicalin were administrated, respectively. The experiment was randomly divided into 4 groups (n=10): Control; I/R; IR+DMEM; and I/R+baicalin groups. Postoperation, the Left Ventricular (LV) End-Diastolic Pressure (LVEDP), the maximum velocity of LV contraction (dP/dtmax) and the maximum velocity of LV diastole (dP/dtmin) were recorded by the transthoracic echocardiography; the myocardial apoptosis percentage was analyzed by Annexin VFITC/ PI and TUNEL staining, and the apoptosis gene and protein were detected by RT-PCR and western blot. Furthermore, the protein expression of the calcium-sensing receptor (CaSR) and ERK1/2 phosphorylation were observed by western blot and Fura-2-acetoxymethyl ester. Moreover, primary rats’ cardiomyocytes were cultured and ERK1/2 specific inhibitor PD98059 was added to the culture medium. The cell survival rate, vitality and apoptosis were detected by MTT, lactate dehydrogenase (LDH) and TUNEL staining assay Kit, respectively.Results: Our present study showed that baicalin significantly improved LV hemodynamic parameters and myocardial apoptosis in myocardial I/R injury rats. Furthermore, we found that baicalin could down-regulate the protein expression of CaSR, but up-regulate the protein expression of ERK1/2. Furthermore, when the cells were pretreated with ERK1/2 inhibitor PD98059, the cells survival rate significantly decreased, but LDH activity and apoptosis significantly increased. The results indicated that the effect of baicalin on myocardial I/R injury could be inhibited by ERK1/2 inhibitor.Conclusion: In conclusion, our data suggests that baicalin attenuates I/R-induced myocardial injury maybe through the suppression of the CaSR/ERK1/2 signaling pathway.
- Open Access
- 22 October 2020
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (23) , 13938-13948
The protective effects of MSC‐EXO against pulmonary hypertension through regulating Wnt5a/BMP signalling pathway
The aim of the study was to explore the mechanism of mesenchymal stem cell‐derived exosomes (MSC‐EXO) to protect against experimentally induced pulmonary hypertension (PH). Monocrotaline (MCT)‐induced rat model of PH was successfully established by a single intraperitoneal injection of 50 mg/kg MCT, 3 weeks later the animals were treated with MSC‐EXO via tail vein injection. Post‐operation, our results showed that MSC‐EXO could significantly reduce right ventricular systolic pressure (RVSP) and the right ventricular hypertrophy index, attenuate pulmonary vascular remodelling and lung fibrosis in vivo. In vitro experiment, the hypoxia models of pulmonary artery endothelial cell (PAEC) and pulmonary vascular smooth muscle cell (PASMC) were used. We found that the expression levels of Wnt5a, Wnt11, BMPR2, BMP4 and BMP9 were increased, but β‐catenin, cyclin D1 and TGF‐β1 were decreased in MSC‐EXO group as compared with MCT or hypoxia group in vivo or vitro. However, these increased could be blocked when cells were transfected with Wnt5a siRNA in vitro. Taken together, these results suggested that the mechanism of MSC‐EXO to prevent PH vascular remodelling may be via regulation of Wnt5a/BMP signalling pathway.
- 22 October 2020
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (23) , 13938-13948
Open AccessThe protective effects of MSC‐EXO against pulmonary hypertension through regulating Wnt5a/BMP signalling pathway
The aim of the study was to explore the mechanism of mesenchymal stem cell‐derived exosomes (MSC‐EXO) to protect against experimentally induced pulmonary hypertension (PH). Monocrotaline (MCT)‐induced rat model of PH was successfully established by a single intraperitoneal injection of 50 mg/kg MCT, 3 weeks later the animals were treated with MSC‐EXO via tail vein injection. Post‐operation, our results showed that MSC‐EXO could significantly reduce right ventricular systolic pressure (RVSP) and the right ventricular hypertrophy index, attenuate pulmonary vascular remodelling and lung fibrosis in vivo. In vitro experiment, the hypoxia models of pulmonary artery endothelial cell (PAEC) and pulmonary vascular smooth muscle cell (PASMC) were used. We found that the expression levels of Wnt5a, Wnt11, BMPR2, BMP4 and BMP9 were increased, but β‐catenin, cyclin D1 and TGF‐β1 were decreased in MSC‐EXO group as compared with MCT or hypoxia group in vivo or vitro. However, these increased could be blocked when cells were transfected with Wnt5a siRNA in vitro. Taken together, these results suggested that the mechanism of MSC‐EXO to prevent PH vascular remodelling may be via regulation of Wnt5a/BMP signalling pathway.